<DOC>
	<DOCNO>NCT01879085</DOCNO>
	<brief_summary>This Phase Ib/II experimental , open-label , dose escalation , active treatment study design determine safety , tolerability , recommend dose combination . During Phase 2 portion study , assess progression-free survival ( PFS ) , overall survival ( OS ) , overall response rate ( ORR ) , correlative endpoint , DNA methylation measure microarray , expression level gene measure microarray</brief_summary>
	<brief_title>Phase 1b/2 Study Vorinostat Combination With Gemcitabine Docetaxel Advanced Sarcoma</brief_title>
	<detailed_description>Phase 1b - To determine dose vorinostat safely combine gemcitabine docetaxel patient advance sarcoma . - To characterize Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) vorinostat combine gemcitabine docetaxel patient advance sarcoma . Phase 2 - To determine safety efficacy gemcitabine docetaxel combination vorinostat patient advanced sarcoma . The hypothesis gemcitabine docetaxel + vorinostat safe improve 6-months progression-free rate ( PFR ) combination 20 % ( 20 % 40 % ) . - To determine objective response rate , progression-free , overall survival patient advance sarcomas treat gemcitabine docetaxel + vorinostat ; - To develop predictive molecular signature response treatment advance sarcoma .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must histologically confirm soft tissue sarcoma evidence metastatic unresectable disease . Patients must measurable disease RECIST 1.1 . Up 32 prior cytotoxic chemotherapy regimens metastatic setting allow . Adjuvant chemotherapy target therapy consider prior line treatment . Age ≥18 year . ECOG performance status ≤2 ( Karnofsky ≥60 % ) . Life expectancy great 12 week . Patients must normal organ marrow function define : leukocyte ≥3,000/µL absolute neutrophil count ≥1,500/µL platelets ≥100,000/µL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤1.5 X institutional upper limit normal ( ULN ) creatinine ≤1.5 X institutional upper limit normal ( ULN ) Peripheral neuropathy , present , ≤grade 1 . Women Child bear potential MUST use contraceptive . Ability understand willingness sign write informed consent document . The follow specific histologic subtypes soft tissue sarcoma exclude : GIST , Kaposi 's sarcoma , mesothelioma , dermatofibrosarcoma , chordoma , alveolar softpart sarcoma . Also , bone sarcoma exclude include Ewing 's sarcoma , osteosarcoma , GIST , low grade chondrosarcoma , chordoma . Patients treatment chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior start study treatment recover adverse event due agent administer 4 week earlier . Patients receive investigational agent . Patients know brain metastasis . History allergic reaction attribute compound similar chemical biologic composition gemcitabine , docetaxel , vorinostat , GCSF . Patients receive progressed combination gemcitabine docetaxel metastatic setting . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant breastfeed woman Patients take concomitant HDAC inhibitor . HIVpositive patient combination antiretroviral treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>unresectable</keyword>
	<keyword>soft</keyword>
	<keyword>tissue</keyword>
	<keyword>sarcoma</keyword>
</DOC>